Literature DB >> 1497574

The extracellular matrix in the failing human heart.

J Schaper1, B Speiser.   

Abstract

The composition of the extracellular matrix was investigated in eight human hearts explanted at the time of transplantation surgery because of endstage cardiomyopathy. All patients showed clinical signs of heart failure. The tissue was investigated by electron microscopy and immunofluorescence microscopy using monoclonal antibodies against collagen I, III, VI, and IV, fibronectin, laminin, and vimentin. All matrix proteins occurred in increased amounts in the extracellular space separating the myocardial cells by septa of enlarged thickness. Laminin and collagen IV surrounded myocardial and endothelial cells as layers of increased thickness. Vimentin localization was normal in individual cells, but occurred more often and corresponded to the numerous fibroblasts as observed by electron microscopy. It is concluded that an excessive deposition of extracellular matrix material in addition to myocyte degeneration (as reported previously (9)) are the structural correlates of cardiac failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497574     DOI: 10.1007/978-3-642-72474-9_26

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  21 in total

1.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

Review 2.  Tissue characterization of the myocardium: state of the art characterization by magnetic resonance and computed tomography imaging.

Authors:  Puskar Pattanayak; David A Bleumke
Journal:  Radiol Clin North Am       Date:  2014-12-18       Impact factor: 2.303

Review 3.  Mechanotransduction: the role of mechanical stress, myocyte shape, and cytoskeletal architecture on cardiac function.

Authors:  Megan L McCain; Kevin Kit Parker
Journal:  Pflugers Arch       Date:  2011-04-19       Impact factor: 3.657

4.  Myocardial T1 mapping: techniques and potential applications.

Authors:  Jeremy R Burt; Stefan L Zimmerman; Ihab R Kamel; Marc Halushka; David A Bluemke
Journal:  Radiographics       Date:  2014 Mar-Apr       Impact factor: 5.333

5.  Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies.

Authors:  E Herpel; S Singer; C Flechtenmacher; M Pritsch; F-U Sack; S Hagl; H A Katus; M Haass; H F Otto; P A Schnabel
Journal:  Virchows Arch       Date:  2005-04-02       Impact factor: 4.064

6.  Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants.

Authors:  U Gabler; A Berndt; H Kosmehl; U Mandel; L Zardi; S Müller; A Stelzner; D Katenkamp
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

7.  Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction.

Authors:  I M Dixon; H Ju; D S Jassal; D J Peterson
Journal:  Mol Cell Biochem       Date:  1996-12-06       Impact factor: 3.396

8.  Protective effects of Jiashen Prescription () on myocardial infarction in rats.

Authors:  Ming-Jun Zhu; You-Ping Wang; Shi-Yang Xie; Wei-Hong Liu; Bin Li; Yong-Xia Wang; He Wang; Bo-Li Zhang
Journal:  Chin J Integr Med       Date:  2014-05-10       Impact factor: 1.978

9.  Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.

Authors:  Toshiyuki Maki; Yoshihisa Nasa; Kouichi Tanonaka; Masaya Takahashi; Satoshi Takeo
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

10.  Increased cardiac workload by closure of the ductus arteriosus leads to hypertrophy and apoptosis rather than to hyperplasia in the late fetal period.

Authors:  Maurice J B van den Hoff; Ronald H Lekanne Deprez; Jan M Ruijter; Piet A J de Boer; Sabina Tesink-Taekema; Anita A Buffing; Wouter H Lamers; Antoon F M Moorman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-31       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.